These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30657798)

  • 1. Crizotinib-induced lichenoid drug eruption in a patient with lung cancer.
    Ho YH; Chen CL
    Cutis; 2018 Dec; 102(6):403-406. PubMed ID: 30657798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.
    Doménech M; Jové M; Aso S; Marín M; Nadal E
    Lung Cancer; 2018 May; 119():99-102. PubMed ID: 29656760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib-Associated Renal Cysts in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients: A Single-Center Experience.
    Eiamprapaporn P; Mungwatthana N; Twinprai P; Sookprasert A; Chindaprasirt J; Ahooja A; Watthanaudomrot S; Sirithanaphol W
    Urol Int; 2020; 104(3-4):269-272. PubMed ID: 31480046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report.
    Wu S; Liu K; Ren F; Zheng D; Pan D
    BMC Pulm Med; 2018 Jul; 18(1):121. PubMed ID: 30029601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Injury during Long-Term Crizotinib Therapy.
    Yasuma T; Kobayashi T; D'Alessandro-Gabazza CN; Fujimoto H; Ito K; Nishii Y; Nishihama K; Baffour Tonto P; Takeshita A; Toda M; Gabazza EC; Taguchi O; Yonemura S; Hataji O
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A; Wood K; Salgia R
    Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis.
    Zhu VW; Lu Y; Ou SI
    Clin Lung Cancer; 2019 Jan; 20(1):e77-e80. PubMed ID: 30318176
    [No Abstract]   [Full Text] [Related]  

  • 10. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex renal cysts combined with hemorrhage during crizotinib treatment for ALK-rearranged lung adenocarcinoma.
    Yang L; Gu J; Niu X
    Cancer Treat Res Commun; 2021; 27():100373. PubMed ID: 33865115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
    Lu S; Yu Y; Fu S; Ren H
    PLoS One; 2018; 13(10):e0205827. PubMed ID: 30352060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
    Mizugaki H; Hamada A; Shibata T; Hosoda F; Nakamura H; Okuma Y; Shukuya T; Umemura S; Horiike A; Fukui T; Kogure Y; Daga H; Urata Y; Yamada K; Saeki S; Fujisaka Y; Nakamura Y; Sato M; Yoshida T; Hotta T; Oizumi S; Fujiwara Y; Ohe Y; Fujiwara Y
    Lung Cancer; 2019 Feb; 128():20-25. PubMed ID: 30642448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma.
    Ota T; Masuda N; Matsui K; Yamada T; Tanaka N; Fujimoto S; Fukuoka M
    Intern Med; 2019 Sep; 58(18):2651-2655. PubMed ID: 31178493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
    Spigel DR; Reynolds C; Waterhouse D; Garon EB; Chandler J; Babu S; Thurmes P; Spira A; Jotte R; Zhu J; Lin WH; Blumenschein G
    J Thorac Oncol; 2018 May; 13(5):682-688. PubMed ID: 29518553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonia caused by crizotinib: case report and review of literature.
    Gou X; Yuan C; Bai Y; Shi L; Xing S; Ma H
    Ann Palliat Med; 2021 Apr; 10(4):4932-4937. PubMed ID: 33040544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
    BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.